文献速递临床试验与 GCP流行病学与生物统计

含蒽环类与含紫杉类化疗用于早期可手术乳腺癌:86项随机试验10万例女性患者水平Meta分析

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials.
PubMed 文献 · Lancet · 2023-01-01

该患者水平Meta分析纳入86项随机试验约10万例早期乳腺癌女性,比较含蒽环类与不含蒽环类的紫杉类方案及不同蒽环-紫杉方案的疗效。含蒽环类的紫杉方案较不含蒽环类者复发率平均降低14%(RR 0.86,95%CI 0.79-0.93;p=0.0004),多西他赛联合环磷酰胺同期加蒽环类10年复发风险12.3% vs 21.0%。作者认为含蒽环类加紫杉类方案降低复发和死亡最有效。

要点

  • 含蒽环类的紫杉方案较不含蒽环类者复发率平均降低14%(RR 0.86,95%CI 0.79-0.93;p=0.0004)。
  • 多西他赛联合环磷酰胺同期加蒽环类10年复发风险12.3% vs 21.0%(RR 0.58,95%CI 0.47-0.73;p<0.0001)。
  • 每700例接受治疗女性中增加1例急性髓系白血病,非乳腺癌死亡未增加。

核心结论

  • 含蒽环类加紫杉类方案在降低乳腺癌复发和死亡方面最有效,蒽环类累积剂量较高的方案获益最大。
  • 该结果对当前临床实践和指南趋向非蒽环类化疗、尤其是较短方案(如四周期多西他赛-环磷酰胺)提出挑战。

研究设计与样本

  • 患者水平Meta分析,比较含与不含蒽环类的紫杉类方案,并更新既往蒽环类方案含与不含紫杉类的Meta分析。
  • 检索MEDLINE、Embase、Cochrane图书馆及会议摘要,纳入2012年1月1日前开始的辅助或新辅助试验。
  • 含与不含蒽环类的紫杉类方案:识别28项试验,23项符合条件,15项提供18103例女性个体数据。
  • 蒽环类方案含与不含紫杉类:35项试验提供52976例个体数据。
  • 另分析44项试验涉及六个相关比较。

主要发现

  • 含蒽环类的紫杉方案较不含蒽环类者复发率平均降低14%(RR 0.86,95%CI 0.79-0.93;p=0.0004)。
  • 多西他赛联合环磷酰胺同期加蒽环类较同剂量多西他赛联合环磷酰胺:10年复发风险12.3% vs 21.0%(风险差8.7%,95%CI 4.5-12.9;RR 0.58,95%CI 0.47-0.73;p<0.0001)。
  • 上述同期加蒽环类组10年乳腺癌死亡率降低4.2%(95%CI 0.4-8.1;p=0.0034)。
  • 序贯紫杉加蒽环类方案较不多西他赛联合环磷酰胺未见复发风险显著降低(RR 0.94,95%CI 0.83-1.06;p=0.30)。
  • 蒽环类方案加紫杉类:各组蒽环类累积剂量相同时RR 0.87(95%CI 0.82-0.93;p<0.0001;n=11167),对照组非紫杉类(多为蒽环类)累积剂量为紫杉组两倍时RR 0.96(95%CI 0.90-1.03;p=0.27;n=14620)。

临床怎么用

  • 作者认为含蒽环类加紫杉类方案降低乳腺癌复发和死亡最有效,蒽环类累积剂量较高的方案获益最大。
  • 作者指出该结果对当前临床实践和指南趋向非蒽环类化疗、尤其是较短方案(如四周期多西他赛-环磷酰胺)提出挑战。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anthracycline-taxane chemotherapy for early-stage breast cancer substantially improves survival compared with no chemotherapy. However, concerns about short-term and long-term side-effects of anthracyclines have led to increased use of taxane chemotherapy without anthracycline, which could compromise efficacy. We aimed to better characterise the benefits and risks of including anthracycline, and the comparative benefits of different anthracycline-taxane regimens. METHODS: We did an individual patient-level meta-analysis of randomised trials comparing taxane regimens with versus without anthracycline, and updated our previous meta-analysis of anthracycline regimens with versus without taxane, as well as analysing 44 trials in six related comparisons. We searched databases, including MEDLINE, Embase, the Cochrane Library, and meeting abstracts to identify trials assessing anthracycline and taxane chemotherapy. Adjuvant or neoadjuvant trials were eligible if they began before Jan 1, 2012. Primary outcomes were breast cancer recurrence and cause-specific mortality. Log-rank analyses yielded first-event rate ratios (RRs) and CIs. FINDINGS: 28 trials of taxane regimens with or without anthracycline were identified, of which 23 were deemed eligible, and 15 provided data on 18 103 women. Across all 15 trials that provided individual data, recurrence rates were 14% lower on average (RR 0·86, 95% CI 0·79-0·93; p=0·0004) with taxane regimens including anthracycline than those without. Non-breast cancer deaths were not increased but there was one additional acute myeloid leukaemia case per 700 women treated. The clearest reductions in recurrence were found when anthracycline was added concurrently to docetaxel plus cyclophosphamide versus the same dose of docetaxel plus cyclophosphamide (10-year recurrence risk 12·3% vs 21·0%; risk difference 8·7%, 95% CI 4·5-12·9; RR 0·58, 0·47-0·73; p<0·0001). 10-year breast cancer mortality in this group was reduced by 4·2% (0·4-8·1; p=0·0034). No significant reduction in recurrence risk was found for sequential schedules of taxane plus anthracycline when compared with docetaxel plus cyclophosphamide (RR 0·94, 0·83-1·06; p=0·30). For the analysis of anthracycline regimens with versus without taxane, 35 trials (n=52 976) provided individual patient data. Larger recurrence reductions were seen from adding taxane to anthracycline regimens when the cumulative dose of anthracycline was the same in each group (RR 0·87, 0·82-0·93; p<0·0001; n=11 167) than in trials with two-fold higher cumulative doses of non-taxane (mostly anthracycline) in the control group than in the taxane group (RR 0·96, 0·90-1·03; p=0·27; n=14 620). Direct comparisons between anthracycline and taxane regimens showed that a higher cumulative dose and more dose-intense schedules were more efficacious. The proportional reductions in recurrence for taxane plus anthracycline were similar in oestrogen receptor-positive and oestrogen receptor-negative disease, and did not differ by age, nodal status, or tumour size or grade. INTERPRETATION: Anthracycline plus taxane regimens are most efficacious at reducing breast cancer recurrence and death. Regimens with higher cumulative doses of anthracycline plus taxane provide the greatest benefits, challenging the current trend in clinical practice and guidelines towards non-anthracycline chemotherapy, particularly shorter regimens, such as four cycles of docetaxel-cyclophosphamide. By bringing together data from almost all relevant trials, this meta-analysis provides a reliable evidence base to inform individual treatment decisions, clinical guidelines, and the design of future clinical trials. FUNDING: Cancer Research UK, UK Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet. 2023. PMID: 37061269. doi:10.1016/S0140-6736(23)00285-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。